Hoth TherapeuticsHOTH
HOTH
About: Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.
Employees: 3
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
18% more funds holding
Funds holding: 11 [Q2] → 13 (+2) [Q3]
1.38% less ownership
Funds ownership: 6.69% [Q2] → 5.31% (-1.38%) [Q3]
10% less capital invested
Capital invested by funds: $327K [Q2] → $293K (-$33.3K) [Q3]
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$3
270%
upside
Avg. target
$4
394%
upside
High target
$5
517%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
D. Boral Capital Jason Kolbert 25% 1-year accuracy 38 / 150 met price target | 517%upside $5 | Buy Maintained | 13 Nov 2024 |
HC Wainwright & Co. Raghuram Selvaraju 39% 1-year accuracy 121 / 308 met price target | 394%upside $4 | Buy Reiterated | 4 Nov 2024 |
Benchmark Bruce Jackson 45% 1-year accuracy 24 / 53 met price target | 270%upside $3 | Speculative Buy Reiterated | 11 Oct 2024 |
Financial journalist opinion
Neutral
PRNewsWire
1 month ago
Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset
NEW YORK , Nov. 20, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient focused biopharmaceutical company, today announced that the Company's Board of Directors approved the purchase of up to $1 million in Bitcoin. "As Bitcoin continues to grow, gaining investor attention and acceptance as a major and primary asset class, we believe that Bitcoin will serve as a strong treasury reserve asset," said Robb Knie, CEO of Hoth.
Neutral
PRNewsWire
1 month ago
Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study
NEW YORK , Oct. 29, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company dedicated to developing new generation therapies for unmet medical needs, is excited to announce highly promising early data from a preclinical study of its latest cancer treatment. The preliminary results demonstrate that the treatment successfully stabilizes tumor growth with remarkable consistency across subjects, showing potential as an effective therapeutic option in oncology.
Neutral
PRNewsWire
2 months ago
Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway
NEW YORK , Oct. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative treatments, is proud to announce the granting of a U.S. patent for its pioneering Alzheimer's treatment, HT-ALZ. This milestone patent secures the company's intellectual property rights to its novel therapeutic approach, as Hoth accelerates preparations for clinical trials.
Neutral
PRNewsWire
3 months ago
Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ
Early observations suggest that the vehicle-treated Alzheimer's mice exhibit a larger population of reactive astrocytes, while the HT-ALZ treated groups show fewer reactive astrocytes, pointing to a potential breakthrough in the treatment of Alzheimer's. NEW YORK, Sept.
Positive
Zacks Investment Research
3 months ago
Hoth Stock Up as Lead Drug Heals Skin Toxicities in Cancer Patient
HOTH stock soars on superior efficacy data from the first patient treated with the lead candidate, HT-001, suffering from EGFRI-related skin toxicities.
Neutral
PRNewsWire
3 months ago
Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial
Dana-Farber Cancer Institute in Boston, MA and Montefiore Medical Center in New York, NY Join Clinical Trial NEW YORK , Sept. 5, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced today that it has received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi).
Neutral
PRNewsWire
3 months ago
Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001
Cancer Patient Ceased Treatment After One Week Due to Rapid Success In the reported case, the patient, a 59-year-old female undergoing treatment at George Washington University for metastatic breast cancer, experienced significant improvement in symptoms just one week after initiating HT-001 therapy. Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment after just seven days.
Neutral
PRNewsWire
4 months ago
Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic
Aronnax to Determine the Maximum-Tolerated Dose (MTD) Post Intravenous Injection Followed by a Dose Range-Finding Phase of Hoth's Orphan Drug HT-KIT NEW YORK , Aug. 15, 2024 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, today announced that it has entered into a Master Services Agreement with Aronnax, Inc. for its HT-KIT cancer therapeutic. HT-KIT research, which was conducted at NC State University to evaluate the efficacy of HT-KIT in cancerous and non-cancerous cells, has demonstrated that HT-KIT effectively kills human mast cells that rely on signaling through the KIT receptor to survive.
Neutral
InvestorPlace
4 months ago
Why Is Hoth Therapeutics (HOTH) Stock Moving Today?
Hoth Therapeutics (NASDAQ: HOTH ) stock is on the move Wednesday after the clinical-stage biopharmaceutical company announced a new partnership with LTS Therapy Systems. This partnership has the two companies working together to accelerate the development of Hoth Therapeutics' candidate for Alzheimer's disease.
Neutral
PRNewsWire
4 months ago
Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment
Treatment of pre-clinical subjects showed cognitive benefits that suggest HT-ALZ's mode of action may involve a reduction in brain inflammation, thereby improving cognitive outcomes for Alzheimer's patients. HT-ALZ's pre-clinical significance lies in its ability to demonstrate marked cognitive improvement and quality of life for subjects suffering from Alzheimer's disease The pre-clinical research shows compelling evidence of HT-ALZ's capacity to improve memory tasks related to the hippocampus and sensorimotor gating, showcasing an important step forward in Alzheimer's disease treatment.
Charts implemented using Lightweight Charts™